Raj Kannan, CEO, Chiasma is focused on bringing to market oral formulations to patients that face significant challenges with their existing injectable therapies. Targeting those suffering from the rare disease acromegaly, recent approval of MYCAPSSA brings the first and only oral somatostatin analog to a predominantly injectable dominated market. Their proprietary delivery technology solves the problem of getting peptides through the stomach and delivering the medication to the intestine. Chiasma is excited about the potential of MYCAPSSA being a new standard of pharmacological care.
#acromegaly #raredisease #ChronicDisorder #biotechnews
Chiasma.com
Download the transcript here
Empowered Patient Podcast